Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
1(10%)
Results Posted
83%(5 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_3
1
10%
Ph phase_2
2
20%
Ph not_applicable
7
70%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
1(10.0%)
N/ANon-phased studies
7(70.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(6)
Terminated(2)
Other(1)

Detailed Status

Completed6
Terminated2
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (20.0%)
Phase 31 (10.0%)
N/A7 (70.0%)

Trials by Status

active_not_recruiting110%
completed660%
unknown110%
terminated220%

Recent Activity

1 active trials
Showing 5 of 10
active_not_recruitingphase_3

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

NCT03927027
completednot_applicable

Lymph Node Mapping in Patients With Endometrial Cancer

NCT01818739
terminatednot_applicable

Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery

NCT01939028
completedphase_2

Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer

NCT01771666
terminatednot_applicable

Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer

NCT00070317
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03927027Phase 3

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

Active Not Recruiting
NCT01818739Not Applicable

Lymph Node Mapping in Patients With Endometrial Cancer

Completed
NCT01939028Not Applicable

Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery

Terminated
NCT01771666Phase 2

Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer

Completed
NCT00070317Not Applicable

Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer

Terminated
NCT00450723Not Applicable

Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer

Completed
NCT00012168Not Applicable

Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat

Completed
NCT00625625Phase 2

Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer

Unknown
NCT00003186Not Applicable

Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer

Completed
NCT00438477Not Applicable

Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10